Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

ings with the Securities and Exchange Commission. These include, without limitation, risks and uncertainties relating to the Company's financial results and the ability of the Company to (1) raise additional capital and continue as a going concern, (2) increase Keflex 750 sales, (3) retain marketing approval for its MOXATAG product, (4) successfully reduce costs, (5) reach profitability, (6) prove that the preliminary findings for its product candidates are valid, (7) receive required regulatory approvals, (8) successfully conduct clinical trials in a timely manner, (9) establish its competitive position for its products, (10) develop and commercialize products that are superior to existing or newly developed competitor products, (11) develop products without any defects, (12) have sufficient capital resources to fund its operations, (13) protect its intellectual property rights and patents, (14) implement its sales and marketing strategy, (15) successfully attract and retain collaborative partners, (16) successfully commercialize and gain market acceptance for its Keflex products, (17) successfully obtain sufficient manufactured quantities of its drug products at acceptable rates, and (18) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. MiddleBrook undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... January 13, 2014 Bob Hainsey, a ... than 20 years in the industry, has joined ... Hainsey will serve as the society’s Science and Technology ... join SPIE as our Technology Strategist, further strengthening the ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... BASINGSTOKE, England and PHILADELPHIA, Pennysylvania, March 3, Shire ... biopharmaceutical company, notes that Renovo Group plc, (LSE:,RNVO) ... latest Phase 2,studies of JUVISTA(R) (human recombinant TGFbeta3) ... (RN1001-319-1010)., Renovo’s press release can be found ...
... and MONTREAL, March 3 /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. ... company,focused on endocrine therapy and oncology, and Paladin ... company, announced today,that they have entered into a ... rights related to the manufacture, production, distribution,marketing, sale ...
... Feb. 29 Wyeth Pharmaceuticals,a division of Wyeth ... U.S. Food and,Drug Administration (FDA) has approved PRISTIQ(TM) ... treat adult patients with major depressive disorder (MDD). ... in the second,quarter of 2008., "We are ...
Cached Biology Technology:Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 2Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 3AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 2FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 4FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 5FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 6FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 7FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 8FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 9
(Date:4/20/2014)... gene expression analysis growing in importance for both ... Mellon University and the University of Maryland have ... up estimates of gene activity from RNA sequencing ... after the famously speedy fish, estimates of gene ... completed in a few minutes, with accuracy that ...
(Date:4/20/2014)... newborn baby a gift of germsgerms that help ... used to fend off infection, may paradoxically interrupt ... babies more susceptible to dangerous pathogens. , ... The Children,s Hospital of Philadelphia (CHOP) sheds light ... microbes play a crucial role in fostering the ...
(Date:4/20/2014)... crop residue to make ethanol and other biofuels reduces ... gasoline, according to a study published today in the ... by a University of Nebraska-Lincoln team of researchers cast ... meet federal mandates to ramp up ethanol production and ... stalks, leaves and cobs in cornfields after harvest -- ...
Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3
... called CD14 binds to substances liberated from the bacteria ... published in the Journal of Biological Chemistry, scientists in ... and showed how it is perfectly suited to bind ... the "Paper of the Week" in the March 25 ...
... number of genes we have in our genome—more than ... genetic truth has often been obscured. The expression of ... host of non-coding sequences, which bind transcription factors and ... coding sequences, whose signatures are easy to spot, the ...
... and MYC cooperate with each other to promote pediatric ... finding, from investigators at St. Jude Children's Research Hospital, ... Biology (MCB). , B-cell lymphoma is a cancer in ... crowd out other blood cells. The St. Jude researchers ...
Cached Biology News:Scientists solve structure of key protein in innate immune response 2Unexpressed But Indispensable -- The DNA Sequences That Control Development 2TEL2 gene cooperates with MYC gene to provoke B-cell lymphomas 2TEL2 gene cooperates with MYC gene to provoke B-cell lymphomas 3
...
Contains L-glutamine...
...
... ZMD.358. Immunogen: Synthetic peptide ... of human mouse and rat ... human and mouse LRP5 proteins. ... controls: mouse LRP5-pSEC-tag-transfected 293T cells ...
Biology Products: